1. Home
  2. ITRM

as 10-07-2025 3:30pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Founded: 2015 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 1
Market Cap: 40.0M IPO Year: 2018
Target Price: $9.00 AVG Volume (30 days): 739.9K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.80 EPS Growth: N/A
52 Week Low/High: $0.61 - $3.02 Next Earning Date: 11-13-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 482.25%

Stock Insider Trading Activity of Iterum Therapeutics plc (ITRM)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Dunne Michael W. ITRM N/A Aug 8 '25 Buy $0.72 15,000 $10,854.00 235,001

Share on Social Networks: